Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association ...
Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a ...
Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors. The eye-disease-focused company plans to list on the New York ...
Strategic appointments fuel global clinical and commercial development of AURN001, a transformational cell therapy with the potential to restore vision Aurion Biotech is developing AURN001, an ...
Aurion Biotech is setting its sights high with a mission to restore vision for millions of patients via regenerative therapies and a $120 million financing round to back the tech. The clinical-stage ...
Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results